{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"6","value":"3.6"},{"groupId":"OG001","lowerLimit":"6","upperLimit":"7","value":"6.3"},{"groupId":"OG002","lowerLimit":"4","upperLimit":"6","value":"4.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"77"}],"units":"Participants"}],"description":"Time to clinical response is defined as the time from the date of first dose received to the first date of assessment of clinical response. Clinical response is defined as a response of CR or PR at any time pre-surgery. Per RECIST v1.0 for target lesions and assessed by mammogram or MRI and CBE, CR is disappearance of all target lesions; PR is \\>=30% decrease in the sum of the longest diameter of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.","id":"OG000","title":"T+P Concomitant Anthracycline-based Chemotherapy"},{"description":"FEC every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.","id":"OG001","title":"T+P Sequential Anthracycline-based Chemotherapy"},{"description":"Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.","id":"OG002","title":"T+P Concomitant Non-Anthracycline Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"ITT population included all participants who were randomized to treatment.","reportingStatus":"POSTED","timeFrame":"Up to 18 weeks","title":"Efficacy: Time to Clinical Response","type":"SECONDARY","unitOfMeasure":"weeks"}